Dalantercept

N/A

Report date: 2024/02/21 12:06:29

Base Information

Drug NameDalantercept
Drug Alias NameACE-041
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionActivin receptor-like kinase 1 inhibitors
TargetsActivin receptor-like kinase 1
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsFallopian Tube Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAcceleron Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAcceleron Pharma IncNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursEndometrial NeoplasmsFallopian Tube Neoplasms +[11] 

Other Information

ATC CodeN/A
Related LinksKEGG